Opening New Therapeutic Strategies for Ovarian Cancer
New Therapeutic Strategies for Ovarian Cancer
- Length
- 51 min
- Level
- Graduate
- Recorded
- Harvard Universityat Yale University2026 · Standalone Lecture
Chapter 1 of 7: Before the lecture
Traces new therapeutic strategies for ovarian cancer across biomarker-driven trials and antibody-drug conjugates.
Ovarian cancer treatment balances newly diagnosed standard therapies with emerging targeted agents for recurrent disease. The talk examines biomarker-driven strategies, including PARP inhibitors for homologous recombination-deficient tumors and antibody-drug conjugates targeting folate receptor alpha. Clinical trial designs such as the Mirasol study highlight the efficacy of mirvetuximab soravtansine against chemotherapy. Combination regimens and novel targets like cell cycle regulators provide additional approaches to overcome drug resistance.

Your comment is kept while you sign up.Sign in
Ovarian cancer treatment balances newly diagnosed standard therapies with emerging targeted agents for recurrent disease. The talk examines biomarker-driven strategies, including PARP inhibitors for homologous recombination-deficient tumors and antibody-drug conjugates targeting folate receptor alpha. Clinical trial designs such as the Mirasol study highlight the efficacy of mirvetuximab soravtansine against chemotherapy. Combination regimens and novel targets like cell cycle regulators provide additional approaches to overcome drug resistance.
DESTINY-PanTumor02
KEYNOTE-B96
ROSELLA study
GOG 218
Van Driel study
SOLO-1
PRIMA
Mechanistic rationale behind PARP inhibitor (PARPi) combinations
Alpha-specific PI3K inhibitor alpelisib + olaparib
Tumour associated antigens targeted with antibody-drug conjugates and their expression levels are shown
History of ADCs for platinum resistant ovarian cancer
Mirasol study
DESTINY-PanTumor02 Trial
Lee et al., IGCS 2024 / Liu et al., ASCO 2025
Ngoi NYL et al., Lancet Oncology 2026
Sellars et al., Nature Medicine 2026
Corcoran et al., CCR 2023
Khan et al., Nature Medicine 2019; Stover et al., Molecular Cancer Research 2019